ジャーニー・メディカルに関するコメント

$ジャーニー・メディカル(DERM.US)$ Director Smith Justin Adam purchased 30,000 shares of Common Stocks on Mar 22, 2024 at an average price of $3.47 for a total value of $104.1K.

$ジャーニー・メディカル(DERM.US)$ Officer Maraoui Claude purchased 10,000 shares of Common Stocks on Mar 22, 2024 at an average price of $3.479 for a total value of $34,790.

$ジャーニー・メディカル(DERM.US)$ Director ROSENWALD LINDSAY A MD purchased 20,000 shares of Common Stocks on Mar 22, 2024 at an average price of $3.4 for a total value of $68,000.

$ジャーニー・メディカル(DERM.US)$ downtrending from long time volume picking up from ladt 3 days bought some with virtual money on time of abaove 25ma test lets see

$ジャーニー・メディカル(DERM.US)$ Journey Medical Corporation Announces FDA Acceptance Of New Drug Application For DFD-29 For Treatment Of Rosacea

My pick for 2/5/2024 🚨⚡️🚨
$ジャーニー・メディカル(DERM.US)$
📊⚡️📊

$ジャーニー・メディカル(DERM.US)$ Journey Medical Corporation Submits New Drug Application To FDA For DFD-29 To Treat Rosacea
Benzinga· just

no news, guys I also reenter after some gains. $フォートレス(FBIO.US)$ . but this one actually has a lot of project, sadly it lack of cash and equity. it seems so they issue warrant monthly. DER still high. potential BEP, but a bit worried if per month issued warrant. it has position as stock holder in $ムスタング バイオ(MBIO.US)$, $ジャーニー・メディカル(DERM.US)$ , $チェックポイント セラピューティクス(CKPT.US)$ .
Hope miracle happens suddenly shows up an acquisition news like $Gracell Biotechnologies(GRCL.US)$ by ...

$ジャーニー・メディカル(DERM.US)$ bought some lets go!

$ジャーニー・メディカル(DERM.US)$ Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea